PAION Announces Patient Recruitment For Phase IIa Study With Its Short Acting Anesthetic Sedative CNS 7056 Successfully Completed
The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces the successful completion of the Recruitment for the Phase IIa clinical trial assessing the new short-acting intravenous anesthetic/sedative CNS 7056 in patients undergoing endoscopy of the upper gastrointestinal tract. "Again our development team has beaten our expectations. We will be able to provide headline data by November, " commented Dr. Wolfgang SÃ hngen, PAION's CEO. "Based on the blinded data already available there are no safety concerns and we expect that this study will support the unique profile of this exciting compound.
95% of patients are suffering from moderate to severe chronic pain after one year of treatment and only 12% are being prescribed strong opioids, according to a year-long survey presented today at the EFIC congress. The research reveals that more than half of patients' pain levels fail to improve over the course of a year's treatment and for 19%, their pain has become worse. Despite the high proportion of patients continuing to suffer pain, 64% of patients believe they are taking the most appropriate level of medication and 58% believe that everything is being done to help them. The new survey, entitled PainSTORY (Pain Study Tracking Ongoing Responses for a Year), is the first of its kind to track the impact of chronic pain on patients' lives over the course of a year and involved 294 patients in 13 European countries.
Until now, the mode of action of nitrogen-containing bisphosphonate (N-BP) cancer drugs, used to relieve bone pain and to prevent skeletal complications in bone metastasis, has been almost entirely unknown. Researchers writing in BioMed Central's open access journal Genome Biology have used 'barcoded' yeast mutants to identify new biological processes involved in the cellular response to N-BPs, opening up opportunities for the development of new anticancer drugs. Daniela Delneri, from the University of Manchester, UK, worked with Gianluca Tell and an Italian team of researchers to carry out the experiments. Delneri said, "We discovered two novel biological processes involved in the cytotoxic effects of the N-BPs, DNA damage and microtubule assembly, and, thanks to the novel 'barcode' approach, these could be linked directly to the responsible genes, DBF4 and TBCB.
Measuring circulation in the ankle using a device similar to a blood pressure cuff can help identify asymptomatic peripheral artery disease (PAD) in stroke and transient ischemic attack (TIA) survivors, a group at much higher risk of subsequent cerebrovascular events, according to a study in Stroke: Journal of the American Heart Association. The ankle brachial index (ABI) compares blood flow in the ankle and the arm to detect poor circulation caused by fatty plaque buildup in the lower body. Researchers used it to screen 102 stroke and TIA survivors. The investigators found that 26 percent of the survivors had asymptomatic PAD, and they had three times more subsequent cardiovascular events - stroke, heart attacks or death - in the following two years compared to those without PAD.
Rheumatoid Arthritis (RA) is a chronic autoimmune disease that causes inflammation of the joints and surrounding tissues. More than 1.3 million adults in the U.S. suffer from RA with 75% of those afflicted being women. Patients with RA experience pain, stiffness, swelling, and deterioration of joints. Severe chronic pain accompanied by progressive joint destruction, disability, and disfigurement is known to increase the risk of experiencing emotional disturbances, with RA patients twice as likely to be depressed as people in the general population. Emotional wellness for persons with RA plays a critical role in disease course and disability.
The Medicines and Healthcare products Regulatory Agency (MHRA) has announced a package of measures to promote the safer use of codeine and dihydrocodeine containing analgesics. This follows a thorough review of the benefits and risks of these medicines. The National Pharmacy Association, as the UK's trade body for pharmacy owners, is supportive of the measures that will encourage consumers to ask their pharmacist for advice about pain relief. We look forward to working with pharmaceutical manufacturers, regulators, consumer groups and our members in implementing these changes. John Turk, NPA Chief Executive, comments: "Pharmacists help people make the right choice about pain relief every day.